The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
NUFYMCO BLA has been approved by the USFDA
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Subscribe To Our Newsletter & Stay Updated
